<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238160</url>
  </required_header>
  <id_info>
    <org_study_id>KYUH-UHA-HCC02-01</org_study_id>
    <secondary_id>CDR0000363800</secondary_id>
    <nct_id>NCT00238160</nct_id>
  </id_info>
  <brief_title>Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer</brief_title>
  <official_title>Phase III Randomized Study of Surgical Resection With Versus Without Postoperative Hepatic Arterial Chemotherapy in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving drugs directly into the arteries around the tumor may kill more tumor cells.&#xD;
      Giving chemotherapy after surgery may kill any remaining tumor cells. It is not yet known&#xD;
      whether surgery and hepatic arterial chemotherapy are more effective than surgery alone in&#xD;
      treating patients with liver cancer that has spread to the portal vein.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying surgery and hepatic arterial&#xD;
      chemotherapy to see how well they work compared to surgery alone in treating patients with&#xD;
      liver cancer that has spread to the portal vein.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of surgical resection with vs without postoperative hepatic&#xD;
           arterial chemotherapy in patients with hepatocellular carcinoma and portal vein tumor&#xD;
           thrombus.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to grade&#xD;
      of portal invasion and Child-Pugh classification. Patients are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients undergo macroscopic curative resection. Within 28 days after surgery,&#xD;
           patients without post-surgery complications undergo hepatic arterial infusion comprising&#xD;
           fluorouracil and cisplatin on days 1-5, 8-12, and 15-19. Treatment continues for 6&#xD;
           months.&#xD;
&#xD;
        -  Arm II: Patients undergo macroscopic curative resection.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Localized Resectable Adult Primary Liver Cancer</condition>
  <condition>Stage III Childhood Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hepatic arterial infusion</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed hepatocellular carcinoma (HCC) with portal vein tumor&#xD;
             thrombus&#xD;
&#xD;
          -  Tumor thrombus in the main trunk or first branch of the portal vein&#xD;
&#xD;
          -  No apparent distant metastases on chest CT scan and bone scintigraphy within the past&#xD;
             6 weeks&#xD;
&#xD;
          -  No pleural effusion or ascites&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 50,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 8 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST &lt; 4 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No severe heart disease&#xD;
&#xD;
          -  No cardiac effusion&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other malignant disease&#xD;
&#xD;
          -  No high risk for esophageal varices rupture&#xD;
&#xD;
          -  No allergy to fluorouracil or cisplatin&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior hepatic arterial chemotherapy&#xD;
&#xD;
          -  No prior systemic chemotherapy for HCC&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iwao Ikai, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kyoto University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto City Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>604-8845</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto-Katsura Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>615-8256</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2006</verification_date>
  <study_first_submitted>October 12, 2005</study_first_submitted>
  <study_first_submitted_qc>October 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

